Zoetis Inc. $ZTS Shares Sold by Wrapmanager Inc.

Wrapmanager Inc. cut its holdings in Zoetis Inc. (NYSE:ZTS) by 21.2% in the second quarter, HoldingsChannel reports. The institutional investor owned 3,107 shares of the company’s stock after selling 835 shares during the quarter. Wrapmanager Inc.’s holdings in Zoetis were worth $485,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of ZTS. Nova Wealth Management Inc. purchased a new position in shares of Zoetis in the 1st quarter valued at approximately $25,000. 1248 Management LLC acquired a new position in Zoetis during the 1st quarter valued at approximately $27,000. Saudi Central Bank purchased a new position in shares of Zoetis in the first quarter worth $29,000. REAP Financial Group LLC raised its holdings in shares of Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after buying an additional 131 shares during the last quarter. Finally, NewSquare Capital LLC lifted its stake in shares of Zoetis by 69.1% during the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after buying an additional 85 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Leerink Partners downgraded Zoetis from an “outperform” rating to a “market perform” rating and cut their target price for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Piper Sandler increased their price objective on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. JPMorgan Chase & Co. reduced their price objective on Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. BTIG Research dropped their target price on Zoetis from $200.00 to $160.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Six analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Zoetis currently has a consensus rating of “Moderate Buy” and an average price target of $180.00.

Zoetis Stock Performance

Shares of ZTS stock opened at $121.04 on Friday. The stock has a market cap of $53.34 billion, a PE ratio of 20.83, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. The business has a 50-day simple moving average of $141.57 and a 200-day simple moving average of $151.73. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 52-week low of $117.26 and a 52-week high of $181.85.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.62 by $0.08. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.Zoetis’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period last year, the company earned $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.7%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s payout ratio is 33.67%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.